ClinicalTrials.gov
ClinicalTrials.gov Menu

Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Lung Transplants From Hepatitis C-Positive Donors (HCV) (SHELTER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03724149
Recruitment Status : Recruiting
First Posted : October 30, 2018
Last Update Posted : February 7, 2019
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
University of Pennsylvania

Brief Summary:
This study is being conducted to determine safety and effectiveness of transplanting lungs from Hepatitis C-positive donors into Hepatitis C-negative patients on the lung transplant waitlist, who will then be treated with Zepatier after transplantation.

Condition or disease Intervention/treatment Phase
Lung Diseases Drug: Zepatier Phase 1 Phase 2

Detailed Description:
Open-labelled pilot clinical trial of Zepatier (MK-5172 and MK-8742/Grazoprevir + Elbasvir) in 10 HCV-negative subjects receiving a lung transplant from a HCV-positive donor. Eligible subjects will receive a lung transplant from a deceased-donor with genotype 1 or 4 HCV, and then will receive 12 weeks of Zepatier after lung transplantation when infection with HCV is confirmed in these lung transplant recipients. Treatment will be complete after 12 weeks.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Lung Transplants From Hepatitis C-Positive Donors
Actual Study Start Date : December 12, 2018
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Zepatier (grazoprevir 100mg and elbasvir 50 mg) Drug: Zepatier
Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.




Primary Outcome Measures :
  1. Post-treatment Sustained Virologic Response (SVR) [ Time Frame: Baseline to 24 weeks ]
    The primary analysis will be based on a calculation of SVR rates (number of subjects with SVR); negative HCV RNA after completing Zepatier therapy) / (number of subjects treated with Zepatier post-heart transplantation)

  2. Major Adverse Events Attributable to HCV Therapy in Post-heart Transplant Patients Post-heart Transplant Patients [ Time Frame: Baseline to 52 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Subject Selection Criteria

Inclusion Criteria:

  • 18-65 years of age
  • Obtained agreement for participation from the lung transplant team
  • No evident contraindication to lung transplantation other than the underlying lung disorder
  • Lung allocation score ≤55
  • Able to travel to the University of Pennsylvania for routine post-transplant visits and study visits for a minimum of 12 months after transplantation
  • No active illicit substance abuse
  • Women must agree to use birth control in accordance with Mycophenolate Risk Evaluation and Mitigation Strategy (REMS) following transplant due to the increased risk of birth defects and/or miscarriage
  • Both men and women must agree to use at least one barrier method of birth control or remain abstinent following transplant due to risk of HCV transmission
  • Inclusion criteria for treatment (not for entry as study patient) will include any detectable HCV RNA by week 4 post-lung transplantation
  • Able to provide informed consent

Exclusion Criteria:

  • Hepatocellular carcinoma
  • HIV positive
  • HCV RNA positive
  • Hepatitis B surface antigen and/or DNA positive
  • Any chronic liver disease (excluding non-alcoholic fatty liver disease (NAFLD)) that is occurring in the setting of persistently elevated liver enzymes (patients with Alpha-1-antitrypsin lung disease without hepatic involvement are eligible)
  • Significant fibrosis (≥F2 on the Fibroscan)—for patients with cystic fibrosis, the cutoff will be 11kPa (cutoff for F2 for patients with chronic cholestatic liver disease), whereas for all other patients the cutoff will be 8kPa (the cutoff for fatty liver disease used in the THINKER study).
  • Pregnant or nursing (lactating) women
  • Known allergy or intolerance to tacrolimus that would require post-transplant administration of cyclosporine, rather than tacrolimus given the drug-drug interaction between cyclosporine and ZEPATIER
  • Waitlisted for a multi-organ transplant
  • Patients with underlying liver disease with or without liver cirrhosis
  • Patients with cystic fibrosis who have underlying liver disease
  • Significant esophageal dysmotlity
  • Patient with systemic sclerosis or other collagen vascular disease with underlying significant esophageal dysmotility
  • Re-transplant candidate
  • Use of ECMO or mechanical ventilation as a bridge to lung transplantation
  • Inability to provide study consent
  • Chronic kidney disease with GFR<50

Relative contraindications for study subjects that will be reviewed on a case-by-case basis by the Lung Transplant Selection Committee and the Principal Investigators:

  • Evidence of end organ damage due to diabetes (e.g. retinopathy, nephropathy, ulcerations) and /or brittle diabetes mellitus (e.g. history of diabetic ketoacidosis) and/or uncontrolled diabetes as evidence by a HgbA1C of 7.5-8.5.
  • Hematologic: Significant coagulation abnormalities, and/or bleeding diatheses.
  • Active or recent solid or liquid malignancy in the past 5 years (apart from select skin malignancies).
  • Patient refusal to receive blood products or transfusions during lung transplant surgery.
  • Psychosocial: Profound neurocognitive impairment with absence of social support.
  • Active mental illness or psychosocial instability
  • Inadequate insurance and/or financial support for post-transplant care.
  • Evidence of drug, tobacco or alcohol abuse within the past six months and failure to satisfy recommended therapy/services/parameters as indicated by social work staff and/or consult team.
  • History of chronic non-adherence to medical recommendations and/or medications
  • PRA >10%.
  • Severe malnutrition, BMI <18
  • Major chronic disabling comorbidity (e.g. lupus, severe arthritis, neurologic diseases, previous stroke with profound residual).
  • Symptomatic or severe vascular disease (History of CABG, Aorta-femoral surgery)

Donor Organ Selection Criteria

Broad goal: To include donors with confirmed genotype 1 or 4 HCV expected to have acceptable post-transplant graft outcomes based on large retrospective lung transplant studies.

Inclusion criteria for donors:

  • Detectable HCV RNA
  • Genotype 1 or 4 HCV
  • Age ≤55 years
  • PaO2/FiO2 ≥300 on FiO2 = 100% and PEEP=5
  • Cigarette use history ≤20 pack years
  • No evidence of cirrhosis
  • No prior treatment of HCV with a DAA-based therapy
  • Can be isolated hepatitis B Core IgG positive, but cannot have a detectable HBV Core IgM, HBSAg, and/or HBV DNA (positive HBV NAT test)

Donor Exclusion Criteria:

  • Donation after circulatory death determination (DCDD)
  • HIV positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03724149


Contacts
Contact: David Goldberg, MD, MSCE (307) 22-THINK thinker@med.upenn.edu
Contact: Rhodalyn Forde-Mclean, MD, MHSE (307) 22-THINK thinker@med.upenn.edu

Locations
United States, Pennsylvania
Hospital of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Principal Investigator: David Goldberg, MD, MSCE         
Principal Investigator: Peter Reese, MD, MSCE         
Sponsors and Collaborators
University of Pennsylvania
Merck Sharp & Dohme Corp.
Investigators
Study Director: Peter Reese, MD, MSCE Perelman School of Medicine at the University of Pennsylvania

Responsible Party: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT03724149     History of Changes
Other Study ID Numbers: 829397
First Posted: October 30, 2018    Key Record Dates
Last Update Posted: February 7, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by University of Pennsylvania:
Lung Disease

Additional relevant MeSH terms:
Hepatitis
Hepatitis C
Hepatitis, Viral, Human
Lung Diseases
Liver Diseases
Digestive System Diseases
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Respiratory Tract Diseases
Elbasvir-grazoprevir drug combination
Antiviral Agents
Anti-Infective Agents